Acumen raises $35.75M, reports positive EBD preclinical data with 14-40x brain penetration

Acumen Pharmaceuticals, Inc.

Gross proceeds of $35.75M from private placement of 10,833,331 shares at $3.30/share; led by RA Capital.
Preclinical data for EBD program: 14-40x brain levels in NHPs vs. native antibodies; low anemia risk.
Subcutaneous dosing feasible; IND submission for lead candidate targeted for mid-2027.
Proceeds primarily to support EBD program preclinical work and working capital.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Acumen Pharmaceuticals, Inc. entered into Registration Rights Agreement with certain institutional accredited investors valued at registration for resale of the Shares pursuant to a registration statement to be filed with the SEC (effective 2026-03-13).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional accredited investors
Value: registration for resale of the Shares pursuant to a registration statement to be filed with the SEC
Effective: 2026-03-13

Exact text from the filing

In connection with the Private Placement, the Company and the Investors entered into a Registration Rights Agreement, dated March 13, 2026 (the “ Registration Rights Agreement ”), providing for the registration for resale of the Shares pursuant to a registration statement (the “ Registration Statement ”) to be filed with the Securities and Exchange Commission (the “ SEC ”) no later than two business days after the date on which the Company files with the SEC its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Acumen Pharmaceuticals, Inc. entered into Securities Purchase Agreement with certain institutional accredited investors valued at 10,833,331 shares of common stock at $3.30 per share; expected gross proceeds ~$35.75 million (effective 2026-03-13).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional accredited investors
Value: 10,833,331 shares of common stock at $3.30 per share; expected gross proceeds ~$35.75 million
Effective: 2026-03-13

Exact text from the filing

On March 13, 2026, Acumen Pharmaceuticals, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain institutional accredited investors named therein (each, an “ Investor ” and collectively, the “ Investors ”), pursuant to which the Company agreed to sell to the Investors, in a private placement (the “ Private Placement ”), 10,833,331 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), at an offering price of $3.30 per Share.

View on SEC.gov

314 material agreements filed in the last 30 days. Browse all material agreements →

Acumen Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-017885

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.